Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, demonstrating a +1.72% change from the ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced in Q1 CY2025, but sales fell by 4.3% year on year ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

Pacific Biosciences of California, Inc. MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended ...

PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the ...

PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research. GutID utilizes PacBio's HiFi sequencing ...

PacBio agreed to acquire Omniome for approximately $600 million upfront consisting of 9.4 million shares of PacBio common stock and $300 million in cash—plus up to $200 million in cash and stock ...

Illumina and PacBio have terminated their merger agreement in the face of regulatory opposition. Illumina is clearly interested in the long-term potential of long-read sequencing and is likely to ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 31 cents in first-quarter 2023, narrower than the year-ago loss of 37 cents.

"Scale matters," says the new CEO. One of the goals of Illumina Inc.'s planned $1.2 billion buyout of PacBio three years ago was to capture a ready-built platform to help scientists peer into DNA ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced the availability of a new computational analysis method — Tandem Repeat Genotyping Tool (TRGT ...